Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00437619
Status:
COMPLETED
Last Update Posted:
2015-12-02
First Post:
2007-02-19
Brief Title:
A Study of Sequential Treatment With Daivobet Betamethasone Dipropionate Plus Calcipotriol and Daivonex Calcipotriol in Patients With Psoriasis
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open Label Study to Evaluate the Clinical Response to Sequential Treatment With Daivobet and Daivonex in Patients With Mild to Moderate Psoriasis
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This single arm study will evaluate the efficacy and safety of sequential treatment with Diavobet betamethasone propionate 05mgg plus calcipotriol hydrate 50 microgramsg once daily for 4 weeks followed by Daivonex calcipotriol hydrate 50 microgramsg twice daily for 4 weeks in the control of signs and symptoms in patients with mild to moderate psoriasis Only patients showing a 50 response to Daivobet will progress to the Daivonex maintenance phase The anticipated time on study treatment is 3 months and the target sample size is 100-500 individuals
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None